First Trust Exchange-traded Fund · net assets $2.81B · 32 holdings as of June 30, 2026. Monthly N-PORT disclosure: the full book, not just equities.
EC: 99.9% · STIV: 0.1% · RA: 0.0%
| Month 1 | Month 2 | Month 3 | |
|---|---|---|---|
| Sales | $10M | $73.7M | $24.5M |
| Reinvestment | $0 | $0 | $0 |
| Redemptions | $20.3M | $11.1M | $74.3M |
| Net realized gain (non-derivative) | $38.5M | $4.27M | $32.8M |
| Net unrealized appreciation (non-derivative) | $5.92M | $204M | $256M |
The three months of the reporting period, as filed; month 3 ends June 30, 2026.
| Holding | Value | % of net assets |
|---|---|---|
| Corcept Therapeutics Inc EC | $157M | 5.60% |
| Neogenomics Inc EC | $144M | 5.12% |
| Veracyte Inc EC | $143M | 5.10% |
| Bruker Corp EC | $122M | 4.32% |
| Alkermes PLC EC | $119M | 4.24% |
| Illumina Inc EC | $110M | 3.92% |
| Krystal Biotech Inc EC | $109M | 3.87% |
| Natera Inc EC | $107M | 3.79% |
| Axsome Therapeutics Inc EC | $104M | 3.71% |
| Neurocrine Biosciences Inc EC | $99.2M | 3.53% |
| Bio-techne Corp EC | $96.5M | 3.43% |
| Arrowhead Pharmaceuticals Inc EC | $95M | 3.38% |
| Biogen Inc EC | $94.8M | 3.37% |
| Exelixis Inc EC | $93.3M | 3.32% |
| Incyte Corp EC | $89.6M | 3.18% |
| Argenx Se EC | $88.1M | 3.13% |
| Halozyme Therapeutics Inc EC | $87.6M | 3.11% |
| Vertex Pharmaceuticals Inc EC | $86.4M | 3.07% |
| Repligen Corp EC | $86.2M | 3.07% |
| Biomarin Pharmaceutical Inc EC | $79.6M | 2.83% |
| Amgen Inc EC | $78.3M | 2.78% |
| Biontech Se EC | $73.9M | 2.63% |
| Genmab A/s EC | $73.8M | 2.62% |
| United Therapeutics Corp EC | $71.9M | 2.56% |
| Alnylam Pharmaceuticals Inc EC | $70.9M | 2.52% |
| Beone Medicines Ltd EC | $69.8M | 2.48% |
| Gilead Sciences Inc EC | $69M | 2.45% |
| Adma Biologics Inc EC | $65.5M | 2.33% |
| Sarepta Therapeutics Inc EC | $64.4M | 2.29% |
| Regeneron Pharmaceuticals Inc EC | $63.2M | 2.25% |
| Dreyfus Government Cash Management Funds STIV | $1.53M | 0.05% |
| Daiwa Capital Markets America Inc. RA | $4.69K | 0.00% |
Loading...
